Blood Cancers Today Staff Writers

Staff Writers

Articles by Blood Cancers Today Staff Writers

Blood Cancers Today Staff WritersMyelofibrosis | April 1, 2024
Momelotinib and ruxolitinib improved bone marrow fibrosis, but changes were not associated with improved outcomes in MF.
Read More
Blood Cancers Today Staff WritersAcute Lymphoblastic Leukemia | April 23, 2024
Efficacy was based on the MRD-negative CR rate at the end of induction.
Blood Cancers Today Staff WritersT-Cell Lymphoma | March 18, 2024
Denileukin diftitox is an IL-2-based immunotherapy for patients with relapsed or refractory CTCL.
Blood Cancers Today Staff WritersMyeloma | March 18, 2024
The 11-member panel of independent experts voted eight in favor and three against.
Blood Cancers Today Staff WritersMyeloma | March 15, 2024
The FDA Oncologic Drugs Advisory Committee voted to recommend approval of the supplemental BLA for cilta-cel in myeloma.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | April 23, 2024
An FDA committee voted that the benefits of imetelstat outweigh the risks for the treatment of anemia in lower-risk MDS.
Blood Cancers Today Staff WritersAcute Lymphoblastic Leukemia | March 6, 2024
The efficacy of inotuzumab ozogamicin was assessed in a multicenter, single-arm, open-label study in 53 pediatric patients.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | February 27, 2024
The CHMP of the European Medicines Agency recommended approval of luspatercept for transfusion-dependent anemia due to MDS.
Blood Cancers Today Staff WritersMyeloma | February 21, 2024
The sBLA was approved for a reduced dosing frequency of 1.5 mg/kg every two weeks in relapsed or refractory myeloma.
Blood Cancers Today Staff WritersPrint | February 8, 2024
Selinexor is an oral inhibitor for the treatment of relapsed or refractory multiple myeloma.
Blood Cancers Today Staff WritersPrint | February 8, 2024
CanScan uses low-depth whole-genome sequencing to detect early cancer signals with 99% specificity.
Blood Cancers Today Staff WritersPrint | February 8, 2024
In a clinical trial, relma-cel demonstrated a three-month ORR of 81.36% in patients with relapsed or refractory MCL.
Blood Cancers Today Staff WritersAcute Myeloid Leukemia | February 8, 2024
Gilead said that it "will not pursue further development of magrolimab in hematologic cancers."
Blood Cancers Today Staff WritersIndolent B-Cell Lymphoma | February 2, 2024
Cancer Research & Treatment Fund (CR&T) invests in research related to the prevention and treatment of blood cancers.
Blood Cancers Today Staff WritersChronic Lymphocytic Leukemia | January 16, 2024
The therapy is currently under investigation in multiple clinical trials.
Blood Cancers Today Staff WritersAggressive B-Cell Lymphoma | February 2, 2024
Researchers collected serial peripheral blood mononuclear cell samples from patients with R/R LBCL treated with axi-cel.